Sustaining the World’s Medicine Supply
India’s position as the “pharmacy to the world” is rooted in its ability to deliver affordable, high-quality medicines at an unparalleled scale. Over the past few decades, the country has emerged as a global leader in generic pharmaceuticals and vaccines, supplying essential drugs to more than 150 countries. This role is particularly critical for developing regions, where access to affordable medicines is often the difference between functioning and failing healthcare systems. From routine antibiotics to life-saving vaccines such as DPT, BCG and measles, Indian pharmaceutical exports underpin large-scale immunisation and treatment programmes worldwide.
India’s strength lies in its cost-efficient manufacturing ecosystem, a robust generics industry and strong regulatory compliance, which together enable it to serve both advanced and emerging markets. In doing so, India has not only built a thriving export sector but also established itself as a cornerstone of global public health. However, this centrality also means that disruptions affecting India’s pharmaceutical supply chains can have far-reaching consequences across the world.
Geopolitical Disruptions and Fragile Supply Chains
The ongoing conflict in Iran and the Middle East, has brought into sharp focus the vulnerabilities embedded within global pharmaceutical supply chains. But what happens when the world’s most critical logistics routes suddenly slow down or shut off? Key transit corridors such as the Strait of Hormuz and major Gulf air routes have been significantly disrupted, leading to delays, reduced cargo capacity and sharply rising costs. As commercial activity through these routes declines, the ripple effects are being felt across industries, but perhaps nowhere more critically than in the movement of essential medicines.
For India, the implications are particularly significant. How resilient is a system that powers global healthcare but depends heavily on imported inputs? Despite its position as a global pharmaceutical powerhouse, India continues to rely on external sources for key raw materials, including intermediates and active pharmaceutical ingredients (APIs). Nearly 70% of vaccine raw materials are sourced internationally, primarily from the United States and China. This raises an important question- Can a country that supplies medicines to the world afford such deep supply-side dependencies?
The effects of the disruption are already becoming visible. Reports studying the repercussions mentioned that API prices have surged significantly within a matter of days, while the supply of critical chemical inputs has become increasingly irregular. Shipping timelines have more than doubled, from roughly 20 days to as long as 45-50 days, while freight costs have risen multiple times due to rerouting and war-related surcharges. What does this mean for the end consumer? Multiple reports have also mentioned that these pressures are now translating into a 5-15% increase in wholesale medicine prices, affecting widely used drugs such as paracetamol, antibiotics and diabetes medications.
While immediate shortages have not yet materialised, the situation points to deeper structural concerns. How long can manufacturers absorb rising costs before they are passed on to patients? And what happens if these disruptions persist? Prolonged instability could affect production cycles, delay exports and disrupt supply to countries that depend heavily on Indian pharmaceuticals. Ultimately, the crisis highlights a fundamental issue that global pharmaceutical supply chains remain fragile, overly dependent on limited sourcing geographies and vulnerable transit routes.
In this context, the current moment is not just a disruption, it is a wake-up call.
Addressing Structural Gaps in India’s Pharma Ecosystem
The current disruptions present an opportunity to rethink and strengthen the resilience of India’s pharmaceutical sector. A key priority is reducing dependence on imported raw materials by scaling up domestic production of APIs and intermediates. Government initiatives such as the Production Linked Incentive (PLI) scheme have already begun to address this gap, but sustained investment and technological advancement will be crucial to achieving self-reliance.
Equally important is the need to diversify sourcing strategies. Diversifying procurement beyond a few countries allows Indian pharmaceutical companies to reduce dependency risks and tap into alternative sourcing regions such as Latin America, Africa and Southeast Asia. This approach should be complemented by the development of long-term supplier partnerships, moving beyond transactional procurement to collaborative models that involve joint planning, risk assessment and co-innovation.
Enhancing supply chain visibility is another critical step. Through risk mapping and scenario planning, firms can identify vulnerabilities across different tiers of suppliers and prepare contingency plans for potential disruptions. Investments in logistics infrastructure, including alternative shipping routes, improved cold chain systems and regional distribution hubs, can further strengthen supply chain reliability. Strategic stockpiling of essential raw materials can also provide a buffer against short-term shocks.
Digital technologies offer additional avenues to improve resilience. Real-time tracking systems, predictive analytics and integrated data platforms can enable better coordination across stakeholders and more efficient response to disruptions. Coupled with supportive policy frameworks, export facilitation measures and regulatory harmonisation, these efforts can enhance the robustness of India’s pharmaceutical ecosystem.
Resilience as the Next Frontier
India’s role as the “pharmacy to the world” carries with it a significant global responsibility. The disruptions caused by the current geopolitical crisis serve as a stark reminder that scale and efficiency must be complemented by resilience and adaptability.
By investing in domestic capabilities, diversifying supply chains and strengthening institutional and logistical frameworks, India can not only safeguard its pharmaceutical sector but also reinforce its position as a reliable and resilient global supplier of essential medicines. In doing so, it will continue to play a central role in ensuring equitable access to healthcare, even in an increasingly uncertain and volatile global environment.